---
title: "Truist’s Suvannavejh Lifts Auvelity Outlook and Sets $310 Price Target on Axsome Therapeutics Buy Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285765329.md"
description: "Mizuho Securities analyst Graig Suvannavejh has maintained a Buy rating on Axsome Therapeutics (AXSM) stock, raising the price target to $310. This revision is driven by an optimistic outlook for Auvelity, with projected peak sales of $5 billion, particularly in major depressive disorder and Alzheimer’s agitation. Despite some skepticism, Suvannavejh believes consensus estimates undervalue Auvelity's potential. Needham also reiterated a Buy rating with a $267 price target on the stock."
datetime: "2026-05-08T18:46:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285765329.md)
  - [en](https://longbridge.com/en/news/285765329.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285765329.md)
---

# Truist’s Suvannavejh Lifts Auvelity Outlook and Sets $310 Price Target on Axsome Therapeutics Buy Rating

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on AXSM stock, giving a Buy rating on May 6.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Graig Suvannavejh has given his Buy rating due to a combination of factors, most notably a substantial upward revision to his valuation of Auvelity, Axsome Therapeutics’ key asset. He now forecasts peak Auvelity sales of $5.0 billion, reflecting stronger expectations in both major depressive disorder and Alzheimer’s-related agitation, and this drives a new price target of $310, implying meaningful upside from current levels.

Suvannavejh also highlights management’s updated peak revenue guidance of at least $8 billion for Auvelity, which incorporates policy risks and signals greater long-term potential than previously assumed. Despite recent share price strength and some investor skepticism about the higher guidance, he believes consensus estimates still underappreciate the full Auvelity opportunity, particularly in Alzheimer’s agitation, and his discounted cash flow analysis supports maintaining a positive stance on AXSM shares.

In another report released on May 6, Needham also reiterated a Buy rating on the stock with a $267.00 price target.

### Related Stocks

- [AXSM.US](https://longbridge.com/en/quote/AXSM.US.md)
- [TFC.US](https://longbridge.com/en/quote/TFC.US.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)

## Related News & Research

- [Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch](https://longbridge.com/en/news/286164148.md)
- [Axsome’s AUVELITY Alzheimer’s Approval Sparks Valuation And Growth Questions](https://longbridge.com/en/news/286077483.md)
- [Axsome Therapeutics Wins FDA Nod for Auvelity in Alzheimer’s Agitation, Launch Set for June](https://longbridge.com/en/news/284906140.md)
- [Poxel wins Japan patent for imeglimine use in type 2 diabetes patients with renal impairment](https://longbridge.com/en/news/287013341.md)
- [Axsome Therapeutics (AXSM) Is Up 11.1% After FDA Clears AUVELITY For Alzheimer’s Agitation Treatment](https://longbridge.com/en/news/285005338.md)